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Fabry Disease (FD) is a rare X-linked lysosomal storage disorder characterized by systemic and ocular involvement. It has been
described an increasing in retinal and conjunctival vessel tortuosity and this feature represents an important marker for the
disease. Currently, there is not an objective method to measure and quantify this parameter. We tested a new semi-automatic
software measuring retinal and conjunctival vessel tortuosity from eye fundus and conjunctival digital images in a group of FD
patients. We performed an observational case-control study evaluating three mathematical parameters describing tortuosity (sum
of angle metric [SOAM], product of angle distance [PAD], triangular index [I2e]) obtained from fundus and conjunctival pictures
of 11 FD patients and 11 age and sex-matched controls. Both eyes were considered. Mann–Whitney test was used to compare the
FD group versus the control group and, within the FD group, male versus female patients. Linear regression analysis was
performed to evaluate the possible association of retinal and conjunctival vessels tortuosity parameters with age and with specific
markers of systemic disease’s progression. )e tortuosity parameters (SOAM, PAD and I2e) were significantly higher in retinal
vessels and in conjunctival nasal vessels in FD patients in comparison with the controls (p � 0.003, p � 0.002, p � 0.001 re-
spectively for retina) (p � 0.023, p � 0.014, p � 0.001 respectively for nasal conjunctiva). No significant association was found
between retinal and conjunctival tortuosity parameters and increasing age or systemic involvement markers. Vessel tortuosity
represents an important clinical manifestation in FD. A computer-assisted analysis of retinal and conjunctival vasculature
demonstrated an increased vessels tortuosity in patients affected by Fabry disease. )is non-invasive technique might be useful to
help the diagnosis in early stages, to establish disease severity and monitor its progression.
1. Introduction
Fabry disease (FD) is an X-linked recessive inborn error of
glycosphingolipid metabolism resulting from deficient or
absent activity of the lysosomal exoglycohydrolase α-ga-
lactosidase A (α-Gal A) [1]. Affected patients cannot ef-
fectively metabolize membrane glycosphingolipids (GSLs),
particularly globotriaosylceramide (Gb3), resulting in its
progressive accumulation in lysosomes and cytoplasm in a
variety of cells, including capillary endothelial cells, renal
cells (podocytes, tubular cells, glomerular endothelial cells,
mesangial and interstitial cells), cardiac cells (car-
diomyocytes and fibroblasts) and nerve cells [2].
)e primary disease process starts in infancy, and clinical
features of FD usually appear in childhood and adolescence.
)e prevalence of FD has been estimated to range be-
tween 1 in 40.000 and 1 in 117.000 male births but the true
prevalence maybe higher, as highlighted by Italian and
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Taiwanese new-born screening studies [3]. FD is caused by
mutations in the GLA gene, located on the long arm of
X-chromosome (Xq22) [4]. As in all X-linked disorders the
more severe phenotype usually is manifested in affected
males [4]. )e clinical manifestations are characterized by
cardiac and neurological dysfunctions, cerebrovascular
disease, renal insufficiency, hearing impairment and oph-
thalmic involvement [4–7].
Specific therapy with recombinant human α-galactosi-
dase represents an important milestone in the management
of Fabry disease [8]. Two forms of recombinant enzyme have
been approved in Europe: agalsidase-α and agalsidase-β,
both administered as intravenous infusion biweekly [9].
)ere is an emerging consensus that Enzyme Replacement
)erapy (ERT) has a limited impact on the long-term
outcomes, however expert physicians have recommended
that ERT should be initiated as early as possible [8, 9]. )is
observation is in accordance with the hypothesis that gly-
colipid clearance is most therapeutically effective before
secondary, irreversible tissue damage has occurred [9–11].
Alternative therapeutic strategies include chaperon therapy,
that offers promises in patients with specific mutations,
which result in misfolding and premature degradation of
mutant α-Gal A [12].
)e ocular signs are important markers in Fabry disease.
Cornea verticillata occurs in over 70% of patients and
consists in sub-epithelial corneal deposits with a spoke-like
appearance. It has been considered the most reliable oph-
thalmological marker for diagnosing Fabry disease [13]
(Figure 1). Lens opacities can usually be observed with two
specific manifestations like anterior capsular or subcapsular
cataract, generally bilateral and wedge-shaped, and radial
posterior subcapsular cataract (Fabry Cataract) [14–21].
Another ocular manifestation of FD is represented by
retinal and conjunctival vessel tortuosity, as well as more
rarely aneurysms of the conjunctival vessels especially in
male patients [15, 22]. Usually ocular abnormalities do not
cause significant visual impairment but they may be very
useful for early diagnosis, monitoring of disease progression
and response to treatment. Unfortunately ocular changes are
very difficult to be quantified. Infact, corneal deposits are
usually very pale and thin and can be poorly imaged [13]. On
the other hand Fabry cataract is relatively rare and the
evaluation of vascular abnormalities is very subjective and
poorly quantifiable.
Recently the quantitative evaluation of vascular changes
in various retinal disorders has been attempted by means of
specific software [23–27]. In a previous paper our group
measured retinal vessel tortuosity in FD patients bymeans of
dedicated software [28]. To date, conjunctival vessel tortu-
osity in FD patients has never been quantified. In the present
work we used a software developed for retinal vessel tor-
tuosity analysis in order to investigate the course of both
retinal and conjunctival vessels in FD, and to try to quantify
vessel tortuosity. )e purpose of our study is to evaluate the
clinical use of a possible quantitative analysis of the retinal
and conjunctival vessels in FD as a diagnostic tool and a
predictive indicator of systemic abnormalities.
2. Materials and Methods
2.1. Study Population. Eleven patients (5 males and 6 fe-
males) with a clinical diagnosis of FD were included in the
study. )e mean age was 51.7 (SD: 15.6; range 30–71) years.
Ten patients were recruited through Fabry Disease Referring
Centre of Careggi Teaching Hospital in Florence, Italy. One
female patient was recruited through the Department of
Medical Genetics, Mater Dei Hospital, Malta.
)e diagnosis of FD was formulated on the basis of the
clinical features of the disease, the deficiency of α-GAL A in
plasma and leucocytes, family history and the presence of
GLA gene mutations.
Exclusion criteria were Snellen best corrected visual
acuity <0.8, myopia ≥6 diopters, hyperopia ≥3 diopters,
astigmatism ≥1.5 diopters, relevant media opacities or ret-
inal disorders. All patients included in our study were di-
agnosed with FD and did not suffer from any other
concurrent significant medical condition. )e control group
consisted of 11 healthy subjects (5 males and 6 females)
recruited from the medical and nursing staff working at the
Eye Clinic of the University of Florence, and their relatives (8
and 3 respectively). All joined the study on a voluntary basis.
)e age range was 30–68 years with a mean age of
46.5± 14.5 years. )e study was approved by the local In-
stitutional Revision Boards and was in agreement with the
principles of the Helsinki Declaration.
All the patients underwent a comprehensive ophthal-
mological examination, including biomicroscopy of the
anterior segment and fundoscopy after dilatation. )e
presence of conjunctival or retinal vessel tortuosity, cornea
verticillata or cataract was subjectively evaluated by spe-
cifically trained ophthalmologists (AS, CL) and these oph-
thalmological findings were carefully imaged.
According to our previous paper [20] some established
parameters were considered representative of systemic in-
volvement such as glomerular filtration rate (GFRmL/min),
New York Heart Association scale (NHYA), interventricular
Maximum Wall )ickness (MWTmm) and neurological
manifestations (history of TIA/stroke). )e estimated glo-
merular filtration rate was determined by the 4-variable
Modification of Diet in Renal Disease (MDRD) equation,
Figure 1: Picture of the anterior segment of a patients included in
our study. It is evident a typical form of cornea verticillata.
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and the interventricular septum diameter was assessed by
echocardiography [29].
)e main clinical data of our series are summarized in
Table 1. In the Table the presence of cornea verticillata and
the detected mutations of our patients are also reported.
2.2. Vascular Imaging. We imaged retina and bulbar con-
junctiva according to a standardized protocol. First a
pharmacological mydriasis was induced using Tropicamide
1% eye drop, and posterior pole pictures were obtained using
a fundus camera with a 45° field of view centred on the
macula (Retinographs TF 450 Plus, Carl Zeiss, Dublin, CA,
USA). For each subject three images were taken of each
sector of bulbar conjunctiva (nasal, temporal, superior and
inferior sector) of both eyes, by means of Retinograph TF
450 Plus (Carl Zeiss, Dublin, CA, USA). For each sector, the
best quality image was selected for processing by three senior
investigators (CL, DB, TV). A sample of retinal and con-
junctival vascular network of one of our patients is shown in
Figure 2. A semi-automated analysis was performed on
digital retinographs and conjunctival pictures, using the
dedicated software specifically engineered by the De-
partment of Informatic Engineering of the University of
Siena [28]. )e images processed by the software were TIFF
format files which uselossless compression, with a resolution
of 1536×1024 pixels and colour depth of 8 bits. From every
digitalized retinograph and conjunctival picture, three se-
nior investigators (CL, DB, TV) extracted the most tortuous
vascular segments (5 for the retina and 3 for each conjuctival
sector) using the mouse to select 3 locations along its course.
)e examiners were blinded about patients’ clinical
conditions.
2.3. Procedure for the Analysis of Retinal and Conjunctival
Pictures. )e length of the retinal segment chosen for
analysis was approximately between 350 and 500 pixels. As
for the conjunctival images the length of the segment chosen
for analysis was approximately between 250 and 400 pixels.
After the selection of the vascular segments of retinal and
conjunctival vessels the software automatically calculated
three tortuosity parameters: Sum of angles metric (SOAM),
Product of angle distance (PAD) and Triangular Index (I2e).
Further mathematical details of the chosen parameters have
been discussed elsewhere [28].
2.4. Statistical Analysis. Mann–Whitney test was used to
compare the FD group versus the control group, both for
fundus and conjunctival vessels and then males versus fe-
males, both in FD and control group. No correction for
multiple testing was performed since we always compared
two groups. Linear regression analysis was first used to
evaluate the possible association between retinal and con-
junctival vessel tortuosity indexes, the possible association of
retinal vessel tortuosity parameters with increasing age and
in FD the possible association of retinal vessel tortuosity
indexes with GFR, IVSD and MSSI, in the cases where these
data were available.
A probability of p< 0.05 was considered statistically
significant. All statistical analyses were carried out using the
SPSS (Statistical Package for Social Sciences, Chicago, USA)
software for Windows (Version 13.0).
3. Results
We evaluated with the dedicated software the retinal and
conjunctival vascular network of, 11 patients affected by FD,
focusing first on the comparison between FD patients and
controls and male vs female FD patients. )e results of FD
patients in comparison with the control group for the dif-
ferent tortuosity indexes are summarized in the following
graphs (Figure 3).
In FD, retinal vessel tortuosity was higher in comparison
with the control group (p � 0.003 for SOAM, p � 0.002 for
PAD, p< 0.001 for I2e). On the other hand in FD con-
junctival vessels were significantly more tortuous than
controls only in the nasal sector (p � 0.023 for SOAM, p �
0.014 for PAD, p � 0.001 for I2e) while this difference was
not statistically significant in the other conjunctival sector.
We did not find differences between Fabry vs control
subjects in males compared to females for all outcome
measures (p< 0.05 for interaction term).
Linear regression analysis did not show any significant
association between retinal and conjunctival vessel tortu-
osity indexes, retinal and conjunctival vascular parameters
and increasing age (both in controls and in FD), retinal and
conjunctival vessel tortuosity parameters at each sector and
systemic involvement markers (in FD patients where these
data were available).
4. Discussion
In our study, a computer-assisted analysis of retinal and
conjunctival vasculature showed an increased vessel tortu-
osity in patients with FD. In fact the three considered
tortuosity parameters (SOAM, PAD and triangular index)
were significantly higher in the FD group than in controls
both for retinal and nasal conjunctival vessels. )ese results
confirm our previous report showing the value of computer-
assisted evaluation of retinal vessel tortuosity in FD, but also
show that the same software may be used to quantify
conjunctival vessel abnormalities [28].
Among the different conjunctival sectors, the nasal
sector shows a major increase of vessel tortuosity for the
three considered parameters and then a significant differ-
ence in comparison with the vessels of the same sector in the
control group. )is result cannot be easily interpreted and
may be due to some peculiar features of the vascular network
in the nasal sector of the bulbar conjunctiva. We can
speculate that the nasal vasculature of the conjunctiva may
present a higher perfusion pressure and be more prone to
arterial wall deformation determined by the bloodstream.
In our FD series vessel tortuosity was not more evident
in males than in females. Even if in an X-linked disorder the
phenotype is usually more severe in males than in females,
our series may be too small to detect intersex differences.
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Moreover in FD several women may sometimes present a
relevant systemic involvement [30].
)e lack of a significant association between retinal and
conjunctival vessel tortuosity parameters is not surprising as
the two vascular regions show relevant anatomical and
physiopathological differences. )is result suggests that the
two vascular networks should be considered independently
in the evaluation of vessel tortuosity in FD. A possible option
is to focus on the conjunctival nasal sector which seems
more clinically interesting as it shows significant difference
between FD and controls.
Retinal and conjunctival vessel tortuosity parameters did
not show significant changes with increasing age. Again this
may be due to the relatively small sample size in our series.
Moreover, even if an increase in vessel tortuosity is expected
with increasing age, this parameter has not been carefully
quantified and specifically evaluated in previous longitudinal
studies.
Similarly, in our series we did not observe with linear
regression analysis a significant association between con-
junctival and retinal vessel tortuosity parameters and the
considered markers of systemic involvement in FD. Previous
investigations suggested a possible predictive value of retinal
vessel tortuosity on the severity of the disease [15], even if
this result has not been replicated in other studies [31]. )is
disagreement may be due some differences in the study
protocol, in the features of the study population and mainly
in the procedure used to evaluate the retinal vessels course.
Further studies are required to establish possible correlations
between ocular vascular abnormalities and disease pro-
gression. Some recent developments in ocular vascular
imaging like OCT Angiography and Adaptive Optics may
offer new chances for this kind of investigation, which may
provide clinically significant information for the manage-
ment of FD patients. Finally, we have previously shown that
vascular tortuosity parameters used in our study are re-
producible, since intra- and inter-observer CV was always
below 2% among normal subjects and below 2.5% among
patients with FD [28].
Finally, we are aware of some limitations of our study.
It is to be noted that the sample size is relatively small,
even if FD is a rare disease and patient recruitment is not easy.
Another possible bias may be represented by the diffi-
culty to distinguish vessel abnormalities directly due to
sphingolipid deposits or secondary to arterial hypertension,
a vascular alteration commonly associated with FD. Primary
arterial hypertension detected prior to diagnosis of FD was
one of the exclusion criteria but 3 patients became hyper-
tensive after the diagnosis of FD is made, as a complication
of the disorder itself.
One also has to take into account the fact that our
computer-assisted evaluation of the vasculature is not
Table 1: Principal clinical findings of our series andmutations. NYHA: NewYork Heart Association;MWT: interventricular maximumwall
thickness; GFR: glomerular filtration rate (mL/min/1,73mq); E.R.T: Enzyme Replacement )erapy; P.C: Pharmacological Chaperone.
Sex Age NYHA MWT (mm) GFR (mL/min) Stroke Phenotype Cornea verticillata Mutation )erapy
Patient 1 F 57 1 14 55.2 Yes Classic Yes p.(Arg301Pro) E.R.T.
Patient 2 F 71 1 14 76 Yes Classic Yes p.(Arg301Pro) P.C.
Patient 3 M 38 2 15 71.5 Yes Classic Yes p.(Met1Val) E.R.T.
Patient 4 F 30 1 14 110 No Classic No p.(Lys240ArgfsX29) No
Patient 5 M 65 2 21 78 No Late-onset No p.(Asn215Ser) E.R.T.
Patient 6 M 53 2 10 50 Yes Classic Yes p.(Cys63Tyr) E.R.T.
Patient 7 F 69 2 13 77 No Classic No p.(Leu243Ser) No
Patient 8 F 61 2 14 75 No Classic Yes p.(Ser364Leufs∗9) E.R.T.
Patient 9 M 35 1 12 130 Yes Classic Yes p.(Ser364Leufs∗9) E.R.T.
Patient 10 F 30 1 8 170 Yes Classic Yes p.(Ser364Leufs∗9) E.R.T.
Patient 11 M 60 1 1 19 Yes Classic Yes p.(Arg112Cys) E.R.T.
(a) (b)
Figure 2: Pictures of retinal and conjunctival vasculature network of a patient included in our study.
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completely objective as the choice of the most tortuous
vessels is dependent on the operator.
Furthermore even if in FD veins and arteries are usually
affected, we did not consider them separately. We chose this
option because sometimes the differentiation between the
two kind of vessels is not easy. We preferred an overall
evaluation of the possible vascular abnormalities, in-
dependently from the type of circulation.
)e choice of the tortuosity parameters is another po-
tential limitation. )ere are a number of mathematical
parameters describing tortuosity [24–26]. In a previous
investigation carried out by our group [28], some of the
tortuosity parameters seemed more suitable than others in
detecting FD retinal vascular abnormalities. We can spec-
ulate that the analysis parameters should be tailored for the
specific condition or disorder under evaluation.
In conclusion, computer-assisted analysis of retinal and
conjunctival vasculature showed increased vessel tortuosity
in the retina and in the nasal conjunctiva, in patients with
FD. )is procedure may be clinically useful for the man-
agement of FD patients as it offers some quantitative scores
that are potentially useful for an early diagnosis, and for
monitoring the progression of the disease and its potential
responses to treatment. )is computer software could also
be used for other vascular retinal disorders such as retinal
vein occlusion or hypertensive retinopathy [32].
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